Eurofins Viracor BioPharma Services, a recognized leader in analytical testing and clinical trial services, is relocating its headquarters and laboratory operations to a new, custom-built 96,000 square foot facility in Lenexa, Kansas. The strategic move, scheduled for completion in September 2025, represents a significant milestone in the company's continued growth and commitment to delivering cutting-edge solutions to the biopharmaceutical industry.
Strategic Separation Enables Focused Growth
The relocation marks a pivotal moment for Eurofins Viracor BioPharma Services, which was formally spun out of Viracor in 2020 to focus exclusively on supporting biopharmaceutical sponsors with specialized analytical and clinical trial services. Until now, both companies operated from the same facility, but the move to a dedicated space allows each organization to better concentrate on its core market—Viracor on clinical diagnostics and Eurofins Viracor BioPharma on biopharma services.
This separation enables both companies to take full advantage of the strategic benefits offered by the Kansas City region, including access to top-tier scientific talent, centralized logistics, and a thriving life sciences ecosystem that fosters innovation and growth.
Advanced Testing Capabilities Drive Expansion
The new facility addresses the increasing demand for advanced testing services, particularly in critical areas including sequencing and precision medicine, cell-based assays, high-complexity flow cytometry, vaccine development and biomarker analysis. These capabilities are essential for evaluating safety and efficacy endpoints such as immunogenicity, neutralizing antibodies, target engagement, and mechanism-of-action studies.
The facility will also support the unlocking of disease biology through next-generation sequencing (NGS) and RNA sequencing, which are critical to the development and validation of novel therapeutics. Eurofins Viracor BioPharma's expanded infrastructure will enhance its ability to support custom assay development, GLP/GCLP-compliant assay validation, and clinical sample testing across all phases of drug development.
State-of-the-Art Infrastructure and Technology
The new facility will house leading-edge analytical platforms, integrated automation systems, and expanded biorepository capacity, enabling faster turnaround times, increased throughput, and improved data integrity. The facility was thoughtfully designed to meet client needs and improve staff efficiency, optimizing sample flow through the lab.
The relocation provides space for new service line launches in the future, supporting the company's commitment to investment, innovation, scalability, and operational excellence. The company's testing needs, both current and future, are rapidly increasing, and the organization was approaching the capacity limits of its previous location.
Seamless Transition Process
The company has developed comprehensive plans to ensure no disruption of critical services during the relocation. A Validation Master Move Plan outlines the phased process, including plans to move and qualify instrumentation so that qualified instruments will be available at both locations during the transition.
The laboratory is tentatively scheduled to open on September 26, 2025, with movement of other functions and personnel conducted in phases throughout the rest of the year to ensure an efficient and orderly transition. Professional services with expertise in moving laboratory equipment will handle the relocation, with requalification performed by qualified Biomedical Equipment and Metrology teams in conjunction with vendor service technicians.
Scientific Expertise and Integrated Solutions
Eurofins Viracor BioPharma's scientific team brings decades of experience in molecular biology, oncology, virology, cell biology, infectious disease and immunology, offering consultative support to sponsors navigating complex regulatory and scientific challenges. The company's collaborative approach and robust quality systems ensure reliable, reproducible results that accelerate clinical development timelines.
As part of the Eurofins Clinical Trial Solutions network, Eurofins Viracor BioPharma Services is positioned to provide integrated solutions across bioanalytical, central laboratory, pathology, specialty testing services, and clinical IMP packaging, supporting global clinical trials with precision, accuracy and efficiency.
